全文获取类型
收费全文 | 218624篇 |
免费 | 12026篇 |
国内免费 | 6270篇 |
专业分类
耳鼻咽喉 | 2756篇 |
儿科学 | 8284篇 |
妇产科学 | 2988篇 |
基础医学 | 16374篇 |
口腔科学 | 4182篇 |
临床医学 | 26517篇 |
内科学 | 39120篇 |
皮肤病学 | 3032篇 |
神经病学 | 10817篇 |
特种医学 | 12148篇 |
外国民族医学 | 22篇 |
外科学 | 33020篇 |
综合类 | 19255篇 |
现状与发展 | 25篇 |
预防医学 | 14795篇 |
眼科学 | 4405篇 |
药学 | 23600篇 |
79篇 | |
中国医学 | 4455篇 |
肿瘤学 | 11046篇 |
出版年
2023年 | 1884篇 |
2022年 | 3662篇 |
2021年 | 8850篇 |
2020年 | 5151篇 |
2019年 | 11106篇 |
2018年 | 5692篇 |
2017年 | 4885篇 |
2016年 | 6863篇 |
2015年 | 9724篇 |
2014年 | 17717篇 |
2013年 | 15354篇 |
2012年 | 18818篇 |
2011年 | 15572篇 |
2010年 | 14371篇 |
2009年 | 13970篇 |
2008年 | 12512篇 |
2007年 | 12578篇 |
2006年 | 10590篇 |
2005年 | 6909篇 |
2004年 | 3367篇 |
2003年 | 2936篇 |
2002年 | 2355篇 |
2001年 | 1870篇 |
2000年 | 1686篇 |
1999年 | 1020篇 |
1998年 | 1438篇 |
1997年 | 1305篇 |
1996年 | 1104篇 |
1995年 | 1166篇 |
1994年 | 1132篇 |
1993年 | 872篇 |
1992年 | 1095篇 |
1991年 | 981篇 |
1990年 | 1026篇 |
1989年 | 1004篇 |
1988年 | 928篇 |
1987年 | 819篇 |
1986年 | 669篇 |
1985年 | 1607篇 |
1984年 | 1806篇 |
1983年 | 1296篇 |
1982年 | 1383篇 |
1981年 | 1366篇 |
1980年 | 1191篇 |
1979年 | 1038篇 |
1978年 | 788篇 |
1977年 | 789篇 |
1976年 | 716篇 |
1975年 | 472篇 |
1974年 | 493篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
目的 探讨PDCA 循环在消化道肿瘤伴糖尿病患者营养全程管理中的效果观察。方法 运用PDCA循环对80例不同程度营养不良的消化道肿瘤伴糖尿病患者实施营养全程管理,比较干预前后患者的体重、BMI指数、糖化血红蛋白、血红蛋白、总蛋白、白蛋白及球蛋白水平。结果 患者血红蛋白、总蛋白、白蛋白及球蛋白水平均有提高,比较差异均有统计学意义(P<0.05)。结论 PDCA循环管理在消化道肿瘤伴糖尿病患者营养全程管理中有较大的优势, 值得推广。 相似文献
102.
《肿瘤代谢与营养电子杂志》2019,6(1):66-69
目的 探讨肿瘤患者化疗后血清微量元素及免疫功能的变化,以及肠内营养支持对上述测定指标的影响。方法 选择 2018 年 3 月至 5 月进入武汉市中心医院化疗的肿瘤患者 19 例,年龄为 18~70 岁;KPS 评分≥ 60。随机分为两组: 9 例患者化疗期间行肠内营养干预,10 例患者未进行营养干预。在化疗前后分别测定血清微量元素和外周血淋巴细胞亚 群,并进行统计学分析。结果 未经营养干预的患者化疗后血清锰含量比化疗前显著减低(P=0.004),化疗后血清铅呈 现临界水平降低(P=0.057);行营养干预的患者血清锌含量显著降低(P=0.013),外周血中NK 细胞比例在化疗后呈 临界水平降低(P=0.059),而 CD4+/CD8+ 之比在化疗后呈临界水平升高(P=0.057)。结论 化疗及营养干预对血清微 量元素浓度有一定的作用;营养干预对外周血T 细胞的分布有一定的影响,表现为NK 细胞比例在化疗后有降低趋势, CD4+/CD8+ 比值有升高趋势。由于病例数较少以及营养干预时间较短,因此有必要增加病例数以及延长营养干预时间并 做进一步深入研究。 相似文献
103.
目的观察重灸中脘穴对脾胃虚寒型2型糖尿病胃轻瘫患者胃肠激素、胃动力学的影响。方法选取符合纳入标准的88例脾胃虚寒型糖尿病胃轻瘫患者,按随机数字表法分为治疗组和对照组,每组44例。对照组采用常规药物治疗,治疗组采用重灸中脘穴治疗。疗程结束后记录并对比分析两组临床疗效、胃肠激素[胃泌素(GAS)、胃动素(MTL)]、胃动力学(胃收缩频率、胃排空时间、胃排空率)、主要临床症状评分等变化。结果治疗组临床疗效明显优于对照组,差异具有统计学意义(P<0.05);两组治疗后GAS、MTL均明显优于治疗前(P<0.05),且治疗组明显优于对照组(P<0.05);两组治疗后胃收缩频率、胃排空时间、胃排空率均明显优于治疗前(P<0.05),且治疗组明显优于对照组(P<0.05);两组治疗后主要临床症状评分均明显优于治疗前(P<0.05),且治疗组明显优于对照组(P<0.05)。结论在常规药物治疗基础上重灸中脘穴治疗脾胃虚寒型2型糖尿病胃轻瘫,可调节胃肠激素,改善胃肠动力,促进胃肠功能恢复。 相似文献
104.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(7):415-421
Myelofibrosis (MF) is a BCR-ABL1− myeloproliferative neoplasm that arises from hematopoietic stem and progenitor cells frequently harboring a somatic driver mutation in 1 of 3 genes: JAK2, CALR, or MPL. The pathologic features of this hematologic malignancy include myeloproliferation, diffuse bone marrow fibrosis, and overactivation of the JAK-STAT pathway, resulting in enhanced inflammatory cytokine release. The common clinical manifestations of MF include systemic symptoms, abnormal peripheral blood count levels, and splenomegaly. However, it has become increasingly appreciated that significant clinical heterogeneity exists among patients with MF. Two distinct MF clinical phenotypes include the myeloproliferative and myelodepletive phenotype, with peripheral blood counts being the main discerning feature. Patients with the myeloproliferative phenotype will present with elevated peripheral blood counts and often experience significant constitutional symptoms and progressive splenomegaly. In contrast, patients with the myelodepletive phenotype will have low peripheral blood counts and will frequently require transfusion support. Current frontline therapies for MF, include ruxolitinib and fedratinib, which can exacerbate cytopenias and thereby pose an impediment to effective treatment of the myelodepletive patient. The present review discusses the clinical and prognostic implications of the myelodepletive phenotype and the therapeutic options and limitations for this subset of patients, representing an unmet clinical need. 相似文献
105.
RongZong Liu WonShik Choi Saket Jain Deepak Dinakaran Xia Xu Woo Hyun Han XiaoHong Yang Darryl D. Glubrecht Ronald B. Moore Hlne Lemieux Roseline Godbout 《Molecular oncology》2020,14(12):3100
Early stage localized prostate cancer (PCa) has an excellent prognosis; however, patient survival drops dramatically when PCa metastasizes. The molecular mechanisms underlying PCa metastasis are complex and remain unclear. Here, we examine the role of a new member of the fatty acid‐binding protein (FABP) family, FABP12, in PCa progression. FABP12 is preferentially amplified and/or overexpressed in metastatic compared to primary tumors from both PCa patients and xenograft animal models. We show that FABP12 concurrently triggers metastatic phenotypes (induced epithelial‐to‐mesenchymal transition (EMT) leading to increased cell motility and invasion) and lipid bioenergetics (increased fatty acid uptake and accumulation, increased ATP production from fatty acid β‐oxidation) in PCa cells, supporting increased reliance on fatty acids for energy production. Mechanistically, we show that FABP12 is a driver of PPARγ activation which, in turn, regulates FABP12''s role in lipid metabolism and PCa progression. Our results point to a novel role for a FABP‐PPAR pathway in promoting PCa metastasis through induction of EMT and lipid bioenergetics.
Abbreviations
- AR
- androgen receptor
- ATP
- adenosine triphosphate
- CN
- copy number
- CPT1
- carnitine palmitoyltransferase I
- CS
- citrate synthase
- EMT
- epithelial–mesenchymal transition
- ET
- electron transfer‐state
- FABP
- fatty acid‐binding protein
- LD
- lipid droplet
- OA
- oleic acid
- PCa
- prostate cancer
- PPAR
- peroxisome proliferator‐activated receptor
- PPRE
- peroxisome proliferator‐activated receptor response element
- TZD
- thiazolidinediones
106.
《European journal of surgical oncology》2020,46(11):2023-2028
IntroductionThe lymph node ratio (LNR), which represents the proportion of metastatic lymph nodes resected, has been found to be a prognostic variable in several cancers, but data for Medullary thyroid carcinoma (MTC) are sparse. The aim of this study was to determine the value of the LNR in predicting outcome in patients with MTC.Materials and methodsA retrospective multicenter study design of 107 patients with MTC who underwent total thyroidectomy with neck dissection between 1984 and 2016. The association of LNR with patient and tumor characteristics and prognostic factors was evaluated.ResultsStudy population consisted of 53.3% female, mean age at diagnosis was 50.3 ± 18.4 years; 16.8% had inherited MTC. LNR was positively correlated with tumor size (p = 0.018) and inversely correlated with age at diagnosis (p = 0.024). A higher LNR was associated with extrathyroidal extension (p < 0.001), multifocality (p = 0.001), bilateral tumor (p = 0.002), distant metastases (p < 0.001), and tumor recurrence (OR = 14.7, p < 0.001). LNR was also correlated to postoperative calcitonin levels (p < 0.001) and carcinoembryonic antigen (p = 0.011). LNR >0.1 was associated with shorter disease-specific survival in patients at risk: tumor larger than 20 mm at diagnosis (p = 0.013), sporadic MTC (p = 0.01), and age above 40 years at diagnosis (p = 0.004). Cox multivariate survival analysis revealed LNR as the only significant independent factor for disease free survival (p = 0.005).ConclusionsThis study showed that LNR correlates well with patient and tumor characteristics and prognostic variables. We suggest that LNR should be considered an important parameter for predicting outcome in MTC. 相似文献
107.
Joshua Demb Esther K. Wei Monika Izano Stephen Kritchevsky Helen Swede Anne B. Newman Michael Shlipak Tomi Akinyemiju Steven Gregorich Dejana Braithwaite 《Journal of Geriatric Oncology》2019,10(2):265-271
Objectives
We examined the association between three inflammatory markers (Interleukin (IL)-6, C-reactive protein (CRP), tumor necrosis factor (TNF)-α) and incident lung cancer using baseline, updated, and averaged inflammatory measures in older adults.Methods
We fitted multivariable Cox models to assess whether circulating levels of inflammation markers were associated with incident lung cancers in the Health Aging, Body and Composition (HealthABC) prospective cohort of 3075 older adults aged 70–79?years at baseline. IL-6 and CRP were measured biennially, whereas TNF-α was measured at baseline.Results
Baseline levels of IL-6 were significantly associated with incident lung cancer risk in a model that adjusted for age, gender, race, and site (Model 1) (Hazard RatioT3 vs. T1: 3.34, 95% Confidence Interval: 1.91, 5.85) and in a model adjusted for health factors linked to chronic inflammation (Model 2) (HR T3 vs. T1: 2.57, 95% CI: 1.41, 4.65). The associations observed in time-updated IL-6 (HR T3 vs. T1: 2.47, 95% CI: 1.43, 4.28), cumulatively averaged IL-6 (HR T3 vs. T1: 2.47, 95% CI: 1.43, 4.35), and baseline CRP levels (HR T3 vs. T1: 1.85, 95% CI: 1.11, 3.08) with incident lung cancer in Model 1 were not statistically significant in Model 2.Conclusions
Baseline CRP and IL-6 levels were associated with increased risk of lung cancer in Model 1 and both models, respectively. Chronic IL-6 inflammation, as quantified by repeated measures was associated with incident lung cancer in Model 1, but not Model 2. Further research is needed to understand the role of CRP and IL-6 in lung carcinogenesis. 相似文献108.
《European journal of surgical oncology》2020,46(6):982-990
IntroductionLung cancer is the leading cause of cancer-death worldwide. The U.S. Preventative Services Task Force (USPTSF) approved screening for current or former smokers aged 55–80 based on the results of the National Lung Screening trial (NLST). Following the NLST, new evidence has emerged from clinical trials and updates to previous trials prior to the anticipated update to the USPSTF guideline. We review the new evidence on lung cancer screening with low dose computed tomography (LDCT) and the surgical implications.MethodsA review of new literature was performed pertaining to lung cancer screening since implementation of UPSTF guidelines. Articles for inclusion were identified by both authors’, then search of the Pubmed and Cochrane database was performed from January 1st, 2013 through February 4th, 2020 using the MeSH search terms: “lung cancer”; “screening”; “low dose CT”. The results of these studies are summarized.ResultsWe identified multiple prospective randomized control trials and meta-analysis since the NLST supporting lung cancer-specific mortality with screening. We identified new nodule classification systems and the development of risk-models which may reduce false positive rates and identify high risk patients not currently eligible for screening. Finally, we discussed the surgical implications of screening.ConclusionNew data supports NLST findings and show ongoing benefit to LDCT for lung cancer screening. Standardized LDCT screening classification has been shown to reduce harm and lower false positive rates. Further study is needed regarding use of risk-modeling. Screening will require an increase in the thoracic workforce to accommodate the amount of surgically operable cancers. 相似文献
109.
《药学学报(英文版)》2020,10(2):327-343
Our recent studies demonstrated that the natural product nobiletin (NOB) served as a promising multidrug resistance (MDR) reversal agent and improved the effectiveness of cancer chemotherapy in vitro. However, low aqueous solubility and difficulty in total synthesis limited its application as a therapeutic agent. To tackle these challenges, NOB was synthesized in a high yield by a concise route of six steps and fourteen derivatives were synthesized with remarkable solubility and efficacy. All the compounds showed improved sensitivity to paclitaxel (PTX) in P-glycoprotein (P-gp) overexpressing MDR cancer cells. Among them, compound 29d exhibited water solubility 280-fold higher than NOB. A drug-resistance A549/T xenograft model showed that 29d, at a dose of 50 mg/kg co-administered with PTX (15 mg/kg), inhibited tumor growth more effective than NOB and remarkably increased PTX concentration in the tumors via P-gp inhibition. Moreover, Western blot experiments revealed that 29d inhibited expression of NRF2, phosphorylated ERK and AKT in MDR cancer cells, thus implying 29d of multiple mechanisms to reverse MDR in lung cancer. 相似文献
110.
Sarah Averbach Othman Kakaire Rachel McDiehl Christine Dehlendorf Felicia Lester Jody Steinauer 《Contraception》2019,99(2):87-93